Milena S Nicoloso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9207556/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<scp><i>CDKN1B</i></scp> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. Journal of Pathology, 2021, 253, 234-245.	4.5	12
2	TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells. Cells, 2020, 9, 6.	4.1	20
3	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 3805.	4.1	17
4	Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis. EBioMedicine, 2019, 46, 79-93.	6.1	13
5	Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA) Journal of Clinical Oncology, 2019, 37, 5564-5564.	1.6	1
6	Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2512.	4.1	30
7	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	7.0	122
8	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	8.8	97
9	Following MicroRNAs Through the Cancer Metastatic Cascade. International Review of Cell and Molecular Biology, 2017, 333, 173-228.	3.2	5
10	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, 2016, 35, 4914-4926.	5.9	63
11	BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress. Cell Death and Disease, 2016, 7, e2374-e2374.	6.3	16
12	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	12.1	111
13	Abstract 1483: Biological and clinical significance of miR-224 in colorectal cancer. , 2014, , .		1
14	HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. Cell Death and Differentiation, 2013, 20, 1675-1687.	11.2	99
15	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
16	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery, 2013, 3, 1302-1315.	9.4	140
17	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Scientific Reports, 2013, 3, 2687.	3.3	104
18	Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. Oncotarget, 2013, 4, 1388-1398.	1.8	44

MILENA S NICOLOSO

#	Article	IF	CITATIONS
19	p63–microRNA feedback in keratinocyte senescence. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1133-1138.	7.1	161
20	Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology, 2012, 142, 886-896.e9.	1.3	174
21	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. PLoS ONE, 2012, 7, e41170.	2.5	59
22	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	7.4	256
23	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952.	1.4	200
24	<i>miRâ€29b</i> and <i>miRâ€125a</i> regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes and Cancer, 2010, 49, 981-990.	2.8	125
25	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death and Differentiation, 2010, 17, 246-254.	11.2	231
26	p27 ^{kip1} Controls Cell Morphology and Motility by Regulating Microtubule-Dependent Lipid Raft Recycling. Molecular and Cellular Biology, 2010, 30, 2229-2240.	2.3	68
27	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	7.0	44
28	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocrine-Related Cancer, 2010, 17, F51-F75.	3.1	53
29	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis, 2010, 31, 208-215.	2.8	68
30	Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility. Cancer Research, 2010, 70, 2789-2798.	0.9	365
31	MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. PLoS ONE, 2009, 4, e7405.	2.5	273
32	MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer. Cancer Research, 2009, 69, 9090-9095.	0.9	229
33	MicroRNAs and cancer—new paradigms in molecular oncology. Current Opinion in Cell Biology, 2009, 21, 470-479.	5.4	219
34	MicroRNAs â€" the micro steering wheel of tumour metastases. Nature Reviews Cancer, 2009, 9, 293-302.	28.4	740
35	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2009, 15, 5060-5072.	7.0	386
36	SnapShot: MicroRNAs in Cancer. Cell, 2009, 137, 586-586.e1.	28.9	223

MILENA S NICOLOSO

#	Article	IF	CITATIONS
37	MicroRNAs: The Jack of All Trades. Clinical Leukemia, 2009, 3, 20-32.	0.2	2
38	MicroRNAs: New Players in AML Pathogenesis. Cancer Treatment and Research, 2009, 145, 169-181.	0.5	2
39	MicroRNA Involvement in Brain Tumors: From Bench to Bedside. Brain Pathology, 2008, 18, 122-129.	4.1	90
40	E2F1-Regulated MicroRNAs Impair TGFβ-Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell, 2008, 13, 272-286.	16.8	818
41	A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13556-13561.	7.1	990
42	MicroRNAs as new biomarkers in oncology. Expert Opinion on Medical Diagnostics, 2008, 2, 115-127.	1.6	4
43	In silico prediction of target SNPs affecting miR-mRNA interaction. , 2008, , .		2
44	Stathmin Activity Influences Sarcoma Cell Shape, Motility, and Metastatic Potential. Molecular Biology of the Cell, 2008, 19, 2003-2013.	2.1	121
45	Association of Wwox with ErbB4 in Breast Cancer. Cancer Research, 2007, 67, 9330-9336.	0.9	99
46	MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 709-716.	2.5	56
47	Fez1/Lzts1 Absence Impairs Cdk1/Cdc25C Interaction during Mitosis and Predisposes Mice to Cancer Development. Cancer Cell, 2007, 11, 275-289.	16.8	67
48	Prostaglandin E2 Inhibits Proliferation and Migration of HTR-8/SVneo Cells, a Human Trophoblast-derived Cell Line. Placenta, 2006, 27, 592-601.	1.5	43
49	Alterations of the Tumor Suppressor Gene ARLTS1 in Ovarian Cancer. Cancer Research, 2006, 66, 10287-10291.	0.9	47
50	HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene, 2005, 24, 6809-6819.	5.9	29
51	p27Kip1-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell, 2005, 7, 51-63.	16.8	259
52	p27kip1 Functional Regulation in Human Cancer: A Potential Target for Therapeutic Designs. Current Medicinal Chemistry, 2005, 12, 1589-1605.	2.4	66
53	Linking Inflammation to Cell Cycle Progression. Current Pharmaceutical Design, 2004, 10, 1653-1666.	1.9	22

54 Small silencing non-coding RNAs: cancer connections and significance. , 0, , 481-496.

0